Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical efficacy of FGLM-NH2+SSSR eye drops for intractable corneal epithelial disorders
jRCTs061180036Recruiting
- Start
- Nov 2006
- Modality
- Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of FGLM-NH2 + SSSR in corneal persistent epithelial defect (PED). Primary endpoint: Time to complete healing for persistent epithelial defect. Started Nov 2006; status: recruiting.
02
Drugs
FGLM-NH2 + SSSR
03
Conditions
corneal persistent epithelial defect (PED)
Beyond the preview
Go deeper on jRCTs061180036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180036.